Press Releases

Apr 16, 2026

Caleb Monroe

Press Releases

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

Zentalis Pharmaceuticals announced encouraging preclinical results for its WEE1 inhibitor, azenosertib, showing efficacy in triple-negative breast cancer (TNBC) models resistant to antibody-drug conjugates. Additionally, real-world data reveal poor outcomes for Cyclin E1-positive ovarian cancer patients under current treatments, emphasizing the unm…

ZNTL

Apr 16, 2026

Marcus Reed

Press Releases

Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details

Surgery Partners, Inc., a leading outpatient surgical services provider, announced that it will release its first quarter 2026 earnings before market open on May 5, 2026, followed by a conference call the same day. The company provides high-quality, cost-effective surgical and ancillary care through over 200 locations in 30 states.

SGRY

Apr 16, 2026

Nina Shah

Press Releases

MediaMelon Joins Akamai Qualified Compute Partner Program to Deliver Real-Time Streaming Analytics at Global Scale

Akamai Technologies announced that MediaMelon, a streaming intelligence company, has joined its Qualified Compute Partner Program as an Independent Software Vendor. MediaMelon's SmartSight platform, providing real-time video streaming analytics and AI-powered insights, will now be integrated and scaled on Akamai's globally distributed cloud. This p…

AKAM

Apr 16, 2026

Derek Hwang

Press Releases

BOSS Zhipin's Sustained Share Repurchases Achieved Over RMB896 Million in 2026

KANZHUN LIMITED, trading as BOSS Zhipin, announced continued share repurchases in 2026 totaling over RMB896 million, demonstrating its strong commitment to enhancing shareholder returns through its ongoing buyback program.

BZ

Apr 16, 2026

Derek Hwang

Press Releases

Essent Group Ltd. Schedules First Quarter Earnings Conference Call for May 8, 2026

Essent Group Ltd., a Bermuda-based holding company providing private mortgage insurance, reinsurance, and title insurance services, announced it will hold a conference call to discuss its Q1 2026 financial results on May 8, 2026. The results will be released before market open that day, with the call accessible both via webcast and phone.

ESNT

Apr 16, 2026

Avery Klein

Press Releases

TTEC Schedules First Quarter 2026 Earnings Release and Webcast of Investor Conference Call

TTEC Holdings, Inc., a global consulting, technology, and managed services company, announced it will release its first quarter 2026 earnings results on May 7, 2026, followed by a webcasted investor conference call on May 8, 2026. The earnings release and webcast provide investors an opportunity to assess the company's financial performance and fut…

TTEC

Apr 16, 2026

Derek Hwang

Press Releases

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Therapeutics Corporation reported that its Compensation Committee granted inducement stock options totaling 43,000 shares to three newly hired employees. These options have a ten-year term, an exercise price equal to the closing stock price on the grant date ($4.59), and vest over four years, designed to incentivize talent acquisition and ret…

CAMP

Apr 16, 2026

Jordan Park

Press Releases

Talen Energy Announces Pricing of Senior Notes

Talen Energy Corporation has priced $4 billion in senior notes due 2031 and 2033 to finance its acquisition of 2,451 MW of power generation capacity and redeem existing higher-coupon debt. The move supports the company's expansion with additional fossil and nuclear assets, strengthening its position in the U.S. power generation market.

TLN

Apr 16, 2026

Maya Rios

Press Releases

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

BioXcel Therapeutics announced a virtual event focused on their commercial launch plan for IGALMI®, targeting the treatment of acute agitation associated with bipolar disorder and schizophrenia in the at-home setting, ahead of the November 14 PDUFA date. Market assessment highlights a significant opportunity with up to 86 million annual addressable…

BTAI

Apr 16, 2026

Nina Shah

Press Releases

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

Pyxis Oncology announced new preclinical data demonstrating that its lead candidate, micvotabart pelidotin (MICVO), a novel antibody-drug conjugate, shows significant anti-tumor activity as monotherapy and synergistic effects when combined with anti-PD-1 therapy in a head and neck squamous cell carcinoma (HNSCC) model. These findings support ongoin…

PYXS

Apr 16, 2026

Marcus Reed

Press Releases

AOI Expands Its Houston-Area Footprint to 900,000 Square Feet to Increase Capacity and Support Future Growth

Applied Optoelectronics, Inc. is expanding its Houston-area facilities by adding two adjacent buildings in Pearland, Texas, increasing its manufacturing capacity by about 388,000 square feet. This move supports the company’s ambitious 2027 capacity targets and positions AOI to scale production of high-speed optical transceivers and laser fabricatio…

AAOI

Apr 16, 2026

Avery Klein

Press Releases

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals announced the presentation of multiple preclinical data posters at the 2026 AACR Annual Meeting demonstrating the potential of their drug candidate rinzimetostat, an allosteric PRC2 inhibitor, to treat prostate cancer, including treatment-resistant forms. The data indicates strong antitumor activity across prostate cancer model…

ORIC

Apr 16, 2026

Maya Rios

Press Releases

Intchains Group Limited Provides Staking Activities Update; Advances Strategic Transformation with AI-Enabled Operating Model to Enhance Efficiency and Productivity

Intchains Group Limited reports active staking of over 8,000 ETH on multiple platforms to optimize returns from its treasury assets, while undertaking a strategic transformation by embedding AI-enabled tools across its operations to enhance efficiency, streamline costs, and drive innovation in its altcoin mining and Web3 infrastructure services bus…

ICG

Apr 16, 2026

Priya Menon

Press Releases

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics announced equity inducement grants of 67,600 Restricted Stock Units to five new non-executive employees as part of its 2025 Employment Inducement Award Plan. The grants aim to attract talent to support the company’s development of late-stage gene therapies targeting retinal diseases and cystic fibrosis.

FDMT

Apr 16, 2026

Ajmal Hussain

Press Releases

USA Rare Earth Appoints Chaitan Kansal as Chief Commercial Officer

USA Rare Earth has appointed Chaitan Kansal as Chief Commercial Officer in a new role to lead global commercial strategy, accelerate customer engagement, and secure long-term offtake agreements. This comes as the company moves from development to active production with recent milestones including commissioning of commercial magnet production and st…

USAR

Apr 16, 2026

Sofia Navarro

Press Releases

QuasarEdge Acquisition Corporation Announces Exercise of Over-Allotment Option

QuasarEdge Acquisition Corporation announced that the underwriters of its recent IPO exercised their over-allotment option to purchase an additional 1.5 million units at $10 per unit, raising total units sold to 11.5 million. The units trade on the NYSE under ticker "QRED U" and consist of one ordinary share plus fractional rights, with separate tr…

Apr 16, 2026

Derek Hwang

Press Releases

Vera Bradley Terminates Existing Shareholder Rights Plan

Vera Bradley, Inc. announced the termination of its existing shareholder rights plan effective April 17, 2026, earlier than the originally scheduled October 11, 2026 expiration. The Board cites a reassessment of control risks through market accumulations and believes the plan is no longer necessary at this time. The company remains committed to pro…

VRA

Apr 16, 2026

Caleb Monroe

Press Releases

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALX Oncology Holdings Inc., a clinical-stage biotechnology company, announced that its Compensation Committee approved an inducement stock option grant of 800,000 shares to Jeff Knight, the newly appointed Chief Development and Operating Officer, as per Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to the closing st…

ALXO

Apr 16, 2026

Priya Menon

Press Releases

Zhihu Inc. Files Its 2025 Annual Report on Form 20-F

Zhihu Inc., a leading online content community in China, has filed its annual report for the fiscal year ended December 31, 2025, on Form 20-F with the U.S. Securities and Exchange Commission. The report includes audited consolidated financial statements and is accessible on the company’s investor relations website. Zhihu offers free hard copies to…

ZH

Apr 16, 2026

Priya Menon

Press Releases

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Revolution Medicines, a Nasdaq-listed late-stage clinical oncology company specializing in RAS-addicted cancer therapies, completed concurrent upsized public offerings of common stock and convertible senior notes totaling approximately $2.2 billion. The net proceeds will be utilized to support research and development, potential commercialization, …

RVMD

Apr 16, 2026

Maya Rios

Press Releases

Hingham Savings Reports First Quarter 2026 Results

Hingham Institution for Savings reported first quarter 2026 earnings showing a 60.2% decrease in GAAP net income per share compared to last year, primarily due to a net loss on equity securities. However, Core net income, excluding equity securities gains/losses, rose 72.3%. Total assets grew slightly to $4.55 billion with retail and commercial dep…

HIFS

Apr 16, 2026

Caleb Monroe

Press Releases

Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

Olema Oncology announced compelling preclinical data for its breast cancer therapies palazestrant and OP-3136 at the 2026 AACR Annual Meeting. Palazestrant, a complete estrogen receptor antagonist and degrader, demonstrated robust anti-tumor activity by recruiting corepressor NCoR1 to fully block estrogen receptor activity. Combined with OP-3136, a…

OLMA

Apr 16, 2026

Hana Yamamoto

Press Releases

New Era Energy & Digital Announces Appointment of Andy Casazza as Chief Corporate Officer

New Era Energy & Digital, Inc. announced the appointment of Andy Casazza as Chief Corporate Officer effective April 28, 2026. Casazza brings extensive experience from the energy sector to support the company’s strategy, capital planning, governance, and execution, particularly in advancing its Texas Critical Data Centers project and related growth …

NUAI

Apr 16, 2026

Jordan Park

Press Releases

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Cardiff Oncology presented preclinical data demonstrating that its oral PLK1 inhibitor, onvansertib, combined with trastuzumab deruxtecan (T-DXd), a HER2-targeted antibody-drug conjugate, shows robust antitumor activity and overcomes resistance in HER2-low breast cancer models. The combination produced high tumor regression rates and good tolerabil…

CRDF

Apr 16, 2026

Maya Rios

Press Releases

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

Xilio Therapeutics announced new preclinical data for XTX601, a masked T cell engager aimed at selectively targeting the tumor-associated antigen CLDN18.2 in gastric, pancreatic, and esophageal cancers. The data demonstrated tumor-selective activation, potent anti-tumor activity in multiple models, and a favorable safety profile in non-human primat…

XLO